Condition: Bronchopulmonary Dysplasia · Sponsor: International Peace Maternity and Child Health Hospital
It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.
This description comes directly from the study's public registry record.
Fu Xuemei · +86 18017313931 · fxmzj2004@163.com
Li Dan · +86 18814100771 · lidan910327@126.com
Always discuss trial participation with your own doctor first.
| International Peace Maternity and Child Health Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07561125